Premium
Oncoproteomics of hepatocellular carcinoma: from cancer markers' discovery to functional pathways
Author(s) -
Sun Stella,
Lee Nikki P. Y.,
Poon Ronnie T. P.,
Fan SheungTat,
He Qing Y.,
Lau George K.,
Luk John M.
Publication year - 2007
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/j.1478-3231.2007.01533.x
Subject(s) - proteomics , stable isotope labeling by amino acids in cell culture , computational biology , hepatocellular carcinoma , mass spectrometry , cancer research , biomarker discovery , tandem mass spectrometry , chemistry , biology , biochemistry , chromatography , gene
Hepatocellular carcinoma (HCC) is a heterogeneous cancer with no promising treatment and remains one of the most prevailing and lethal malignancies in the world. Researchers in many biological areas now routinely identify and characterize protein markers by a mass spectrometry‐based proteomic approach, a method that has been commonly used to discover diagnostic biomarkers for cancer detection. The proteomic research platforms span from the classical two‐dimensional polyacrylamide gel electrophoresis (2‐DE) to the latest Protein Chip or array technology, which are often integrated with the MALDI (matrix‐assisted laser‐desorption ionization), SELDI (surface‐enhanced laser desorption/ionization) or tandem mass spectrometry (MS/MS). New advances on quantitative proteomic analysis (e.g. SILAC, ICAT, and ITRAQ) and multidimensional protein identification technology (MudPIT) have greatly enhanced the capability of proteomic methods to study the expressions, modifications and functions of protein markers. The present article reviews the latest proteomic development and discovery of biomarkers in HCC that may provide insights into the underlying mechanisms of hepatocarcinogenesis and the readiness of biomarkers for clinical uses.